Gland Pharma's Pashamylaram unit completes USFDA inspection (11:36, 18 Jan 2025)
Back
Gland Pharma announced that following the Inspection for Good Manufacturing Practices (GMP) by US FDA at the Company's Pashamylaram Facility at Hyderabad between 25 July, 2024 and 02 August, 2024; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection. Powered by Commodity Insights |